Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

NCT05131477 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Eczema
Atopic Dermatitis

Interventions

DRUG: Amlitelimab
DRUG: Placebo

Sponsor

Kymab Limited

Collaborators

[object Object]